Advisor Resource Council Makes New $229,000 Investment in Pfizer Inc. (NYSE:PFE)

Advisor Resource Council bought a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 7,901 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

Other hedge funds have also recently bought and sold shares of the company. Olistico Wealth LLC bought a new position in Pfizer in the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer in the 2nd quarter valued at about $29,000. Quarry LP bought a new position in Pfizer in the 2nd quarter valued at about $31,000. Financial Connections Group Inc. bought a new position in Pfizer in the 2nd quarter valued at about $34,000. Finally, ESL Trust Services LLC bought a new position in Pfizer in the 1st quarter valued at about $37,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on PFE. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Wells Fargo & Company lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Up 0.4 %

Shares of NYSE PFE opened at $27.46 on Friday. The company has a market capitalization of $155.62 billion, a P/E ratio of 37.11, a price-to-earnings-growth ratio of 0.88 and a beta of 0.67. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The company’s 50 day moving average price is $28.96 and its 200-day moving average price is $28.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.17) EPS. Equities analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.12%. Pfizer’s payout ratio is presently 227.03%.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.